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Abstract
Background: Alpha-defensins, which are major constituents of neutrophil azurophilic granules,
and beta-defensins, which are expressed in airway epithelial cells, could contribute to the
pathogenesis of chronic obstructive pulmonary disease by amplifying cigarette smoke-induced and
infection-induced inflammatory reactions leading to lung injury. In Japanese and Chinese
populations, two different beta-defensin-1 polymorphisms have been associated with chronic
obstructive pulmonary disease phenotypes. We conducted population-based association studies to
test whether alpha-defensin and beta-defensin polymorphisms influenced smokers' susceptibility to
lung function decline and susceptibility to lower respiratory infection in two groups of white
participants in the Lung Health Study (275 = fast decline in lung function and 304 = no decline in
lung function).
Methods:  Subjects were genotyped for the alpha-defensin-1/alpha-defensin-3 copy number
polymorphism and four beta-defensin-1 polymorphisms (G-20A, C-44G, G-52A and Val38Ile).
Results: There were no associations between individual polymorphisms or imputed haplotypes
and rate of decline in lung function or susceptibility to infection.
Conclusion: These findings suggest that, in a white population, the defensin polymorphisms tested
may not be of importance in determining who develops abnormally rapid lung function decline or
is susceptible to developing lower respiratory infections.
Background
Chronic obstructive pulmonary disease (COPD) is charac-
terized by irreversible airflow obstruction due to chronic
inflammation. COPD is closely related to cigarette smok-
ing, which is the main environmental risk factor. Longitu-
dinal studies show that only a minority of cigarette
smokers develop airflow limitation,[1] suggesting that
other environmental or genetic factors are important.
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Family and twin studies provide further evidence that
genetic factors play a key role in the etiology of this dis-
ease.[2,3] Inherited deficiency of alpha-1 antitrypsin is
associated with COPD; other genetic risk factors remain to
be identified.
Defensins are small (29–47 amino acids) cationic micro-
bicidal peptides that form part of both the innate and
adaptive immune responses. Defensins show activities
against Gram-positive and Gram-negative bacteria, fungi,
yeast, and enveloped viruses.[4] Defensins are known pri-
marily for their antimicrobial activities; however, the
scope of their activities extends beyond immune
responses and some of these functions could contribute to
lung injury. [5-9]
Based on a characteristic three-dimensional fold and a 6-
cysteine/3-disulfide pattern, human defensins are divided
into two groups, alpha-defensins and beta-defensins.[10]
Three closely related alpha-defensins, alpha-defensin-1
(DEFA1), DEFA2, and DEFA3, are major constituents of
neutrophil azurophilic granules (30–50% of the total pro-
tein content)[11] and play a role in antimicrobial activity
and inflammation in the lung. Beta-defensin-1 (DEFB1) is
constituatively expressed in airway epithelia and plays an
important role in mucosal immunity in the lung.[12,13]
In humans, five alpha-defensins and at least four beta-
defensins are clustered in a 450 kb region on chromo-
some 8p23.[14,15] DEFA1, DEFA2, and DEFA3 differ by
only one amino acid. DEFA2 is the proteolytic product of
DEFA1 and/or DEFA3; DEFA1 and DEFA3 are encoded by
separate genes.[16] Due to a copy number polymor-
phism, individuals can inherit variable copy numbers of
the DEFA1 and DEFA3 genes, and the DEFA3 gene is often
absent.[16] Genetic variation in the DEFB1 gene is associ-
ated with COPD phenotypes in Japanese [17] and Chi-
nese [18] populations.
We determined whether inheritance of both DEFA1 and
DEFA3 genes, rather than the DEFA1 gene only, was asso-
ciated with fast decline in lung function. In addition, we
determined the frequency of four DEFB1 polymorphisms
in the Lung Health Study participants. We also investi-
gated the relationship between the defensin polymor-
phisms and smokers' susceptibility to lower respiratory
infection.
Methods
Study subjects
Subjects were selected from participants in Phase I of the
National Heart, Lung, and Blood Institute (NHLBI) Lung
Health Study. Details of the study have been previously
published.[19] Briefly, study participants were current
smokers, 35–60 years of age, who had mild to moderate
airflow obstruction (FEV1 55–90% predicted and FEV1/
FVC ≤ 0.70). The primary outcome variable was rate of
decline in post-bronchodilator FEV1 over a follow-up
period of five years. Lower respiratory infection rate was
quantified using the number of self-reported visits to a
physician and days in bed for lower respiratory infection
at each follow-up. Of the 3216 continuing smokers in this
cohort, 275 were chosen with a fast decline in lung func-
tion (decline in percent predicted FEV1 > 3.0% per year),
and 304 were selected with no decline in lung function
over the same period (increase in percent predicted FEV1
> 0.4% per year). All 579 selected participants were white
and non-Hispanic. In addition, 27 African American Lung
Health Study participants were genotyped; the data were
used to determine the prevalence of genotypes across
racial groups.
Genotyping
Restriction fragment length polymorphism analysis was
performed in order to distinguish the DEFA1 and DEFA3
genes.[14] An amplicon of 950 bp was generated by 35
cycles of PCR using the sense primer 5'-CAGCGGACATC-
CCAGAAGTGG and the antisense primer 5'-GCGTTTT-
GGTACGTGTATCC. PCRs were performed in a total
reaction volume of 20 μL with 100 ng of genomic DNA,
0.5 U Taq polymerase (Invitrogen), 10X PCR buffer (Inv-
itrogen), 3 mM Mg2+, 0.4 μM forward and reverse primers,
and 200 μM dNTPs. After the initial denaturation at 95°C
for 15 min, the reaction mixture was subjected to 35 cycles
of 94°C for 30 s, annealing for 30 s at 57°C, and 72°C for
30 s followed by the final extension at 72°C for 5 min.
After PCR, 20 μL of the reaction mixture was digested with
1.25 U Hae III restriction endonuclease (New England
BioLabs Inc., Beverly, MA). The digest mixture was
resolved on a 2% agarose gel stained with ethidium bro-
mide. DNA from individuals with DEFA1 only produced
two bands, one at 300 bp and one at 650 bp, and individ-
uals with both DEFA1 and DEFA3 produced all three
bands. Genotyping of the DEFB1 polymorphisms at posi-
tions -20, -44, and -52 in the 5' untranslated region were
performed by restriction fragment length polymorphism
analysis.[14] An amplicon of 260 bp was generated by 35
cycles of PCR using the sense primer 5'-GTGGCACCTC-
CCTTCAGTTCCG and the antisense primer 5'-CAGCCCT-
GGGGATGGGAAACTC. PCRs were performed in a total
reaction volume of 60 μL with 100 ng of genomic DNA,
0.5 U Taq polymerase (Invitrogen), 10X PCR buffer (Inv-
itrogen), 1.5 mM Mg2+, 0.75 μM forward and reverse
primers, and 200 μM dNTPs. After the initial denaturation
at 95°C for 15 min, the reaction mixture was subjected to
35 cycles of 94°C for 30 s, annealing for 30 s at 67°C, and
72°C for 30 s followed by the final extension at 72°C for
5 min. After PCR, 20 μL of the reaction mixture was
digested with 2 U Scr FI restriction endonuclease (New
England BioLabs Inc.) to detect variation at position -20.Respiratory Research 2006, 7:76 http://respiratory-research.com/content/7/1/76
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The digest mixture was resolved on a 3% agarose gel
stained with ethidium bromide. DNA from individuals
with the homozygous G genotype (GG) produced three
bands at 136 bp, 118 bp, and 6 bp; the homozygous A
genotype (AA) produced two bands, one at 254 bp and
one at 6 bp; and the heterozygous genotype (GA) pro-
duced all four bands. 20 μL of the reaction mixture was
digested with 4 U Hga I restriction endonuclease (New
England BioLabs Inc.) to detect variation at position -44.
The digest mixture was resolved on a 3% agarose gel
stained with ethidium bromide. DNA from individuals
with the homozygous C genotype (CC) produced two
bands, one at 71 bp and one at 189 bp; the homozygous
G genotype (GG) produced three bands at 71 bp, 30 bp,
and 159 bp; and the heterozygous genotype (CG) pro-
duced all three bands. 20 μL of the reaction mixture was
digested with 2 U Nla IV restriction endonuclease (New
England BioLabs Inc.) to detect variation at position -52.
The digest mixture was resolved on a 3% agarose gel
stained with ethidium bromide. DNA from individuals
with the homozygous G genotype (GG) produced three
bands at 108 bp, 122 bp, and 30 bp; the homozygous A
genotype (AA) produced two bands, one at 230 bp and
one at 30 bp; and the heterozygous genotype (GA) pro-
duced all four bands. The DEFB1 Val38Ile polymorphism
was analyzed as previously described.[17] Template-free
controls and known genotype controls were included in
each experiment. Twenty samples were selected at random
and sequenced to confirm the genotyping protocols. Gen-
otypes were assigned by two independent investigators
who were unaware of the patients' identities and pheno-
types. Inconsistencies were resolved by two additional
genotyping reactions.
Statistical analysis
Hardy-Weinberg equilibrium tests and linkage disequilib-
rium estimation were performed using Arlequin version
2.0.[20] Haplotype frequencies were estimated using
PHASE version 2.0.[21,22] The chi-square test was used to
test for association of genotype with decline in lung func-
tion status. Logistic regression was then performed to
adjust for the potential confounding factors of age, sex,
smoking history (pack-years), methacholine responsive-
ness, and initial level of lung function (pre-bronchodila-
tor FEV1 percent predicted). Both analyses were
performed using JMP Version 5.1. The infection outcomes
of physician visits/year and days in bed/year are highly
right-skewed, with a high proportion of subjects having
no infection outcomes. To handle this type of data, a two-
part model was used.[23,24] The first part deals with the
spike of observations at zero and models which factors
contribute to a person developing infection-related out-
comes. The second part models the severity, duration
(days in bed/year), or frequency (physician visits/year) of
the infection related outcomes in those who had an out-
come. For the first part of the model, logistic regression
was used to test for association with the presence of at
least one infectious event in a year. The data for the second
part consists only of those with an infection related out-
come and is highly skewed. Generalized Linear Model
regression, assuming gamma distributed observations and
a log link,[25] was then used to test for association of gen-
otype with the average number of infectious events per
year in those having any such events. For both regression
analyses, rate of decline was included as a factor and both
were performed using R http://www.r-project.org. All hap-
lotype analyses were performed using a contributed R pro-
gram called Hapassoc, which tests for haplotype-
phenotype association when haplotype phase is
unknown.[26,27] The power calculator used is available
through the UCLA Department of Statistics http://calcula
tors.stat.ucla.edu/powercalc/. Power calculations for a
sample size of n = 275 cases and n = 304 controls were
performed using a two sided test with the observed allele
frequencies, alpha = 0.05, and beta = 0.80. Statistical sig-
nificance was defined at the 5% level.
Results
General characteristics
The study population consisted of 579 white and non-
Hispanic smokers; 275 smokers with a fast decline in lung
function and 304 smokers with no decline in lung func-
Table 1: Description of the study population.
Variable Fast decline (n = 275) No decline (n = 304) p Value*
Age, yr† 49.5 (6.4) 47.6 (6.9) 0.0007
Sex, n (%) 163 men (59) 203 men (67) 0.06
Smoking history, pk yrs†‡ 43.3 (19.1) 38.3 (18.1) 0.0005
Baseline FEV1, % predicted†§ 72.7 (8.9) 75.7 (8.1) <0.0001
Methacholine response†ll -23.4 (32.7) -7.5 (14.0) <0.0001
* p Values derived from Wilcoxon test or chi-square analysis.
† Mean (SD).
‡ Number of packs of cigarettes smoked per day × number of years of smoking.
§ Lung function at the start of the study as measured percent predicted FEV1 (postbronchodilator).
ll Measurement of the responsiveness of the airways to methacholine expressed as percent decline in FEV1 per final cumulative dose of 
methacholine administered[36] Methacholine response is strongly associated with rate of decline in lung function[37,38]Respiratory Research 2006, 7:76 http://respiratory-research.com/content/7/1/76
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tion over the five year study period. The characteristics of
the study group are described in Table 1. Age, sex, smok-
ing history (pack-years), baseline FEV1, and metha-
choline response differed significantly between the two
groups.
DEFA1 and DEFA3 genes and rate of decline in lung 
function
The number of individuals who had a copy of the DEFA1
gene only (n = 64; 31 fast decline and 33 no decline),
rather than copies of both DEFA1 and DEFA3 genes (n =
515; 244 fast decline and 271 no decline), was not signif-
icantly different in the fast decline in lung function group
(11.8%) compared with the no decline in lung function
group (10.9%), p = 0.87. No individuals in the study
group inherited a copy of the DEFA3 gene alone. Logistic
regression modeling to adjust for confounding variables
confirmed the lack of association (p = 0.99).
DEFB1 gene polymorphisms and rate of decline in lung 
function
Genotypic frequencies of the three DEFB1 SNPs (G-20A,
C-44G, and G-52A) analyzed are given in Table 2. The
observed distribution of all three genotypes was consist-
ent with Hardy-Weinberg equilibrium. Univariate analy-
sis did not suggest any significant associations with the
genotypes and rate of decline in lung function. Logistic
regression modeling to adjust for confounding variables
confirmed the lack of association (G-20A, p = 0.82; C-
44G, p = 0.66; and G-52A, p = 0.76). Subjects were also
genotyped for the DEFB1 Val38Ile SNP. Only one hetero-
zygous subject was detected, suggesting that this polymor-
phism is very rare (<1%), at least in whites.
DEFB1 linkage disequilibrium and haplotype association 
analysis
There was strong linkage disequilibrium between the
three DEFB1 SNPs in the 5' untranslated region (Table 3).
Seven haplotypes were revealed. The estimated haplotype
frequencies in the two Lung Health Study groups are given
in Table 4. Univariate analysis did not suggest any signifi-
cant association between haplotypes and rate of decline in
lung function. The three most common haplotypes (GCA,
ACG, and GGG) were detected in two other studies and
were the only haplotypes reported by those stud-
ies.[17,28]
Secondary outcomes analysis
Statistical analysis did not suggest any significant associa-
tions between genotypes (Table 5) or haplotypes (Table
6) and infection outcomes.
Alpha-defensin and beta-defensin polymorphisms in 
different racial groups
We determined the prevalence of genotypes across white
and African American participants of the Lung Health
Study and found statistically significant differences
between racial groups (Table 7).
Discussion
We investigated the role of alpha-defensin and beta-
defensin polymorphisms in promoting FEV1 decline in
smokers with COPD and the influence on smokers' sus-
Table 2: Beta-defensin-1 genotypic frequencies by fast decline or no decline in lung function status. Frequencies shown, n (%).
Polymorphism Phenotype Genotype
G-20A GG GA AA
(rs11362) Fast decline 83 (30.2) 131 (47.6) 61 (22.2)
No decline 91 (29.9) 150 (49.3) 63 (20.7)
*p = 0.89
C-44G CC CG GG
(rs1800972) Fast decline 177 (64.4) 85 (30.9) 13 (4.7)
No decline 198 (65.1) 91 (29.9) 15 (4.9)
*p = 0.97
G-52A GG GA AA
(rs1799946) Fast decline 107 (38.9) 128 (46.6) 40 (14.6)
No decline 130 (42.8) 128 (42.1) 46 (15.1)
*p = 0.55
* p Values derived from chi-square test.
Table 3: Beta-defensin-1 linkage disequilibrium.
D' (D/Dmax) r2 p Value*
G-20A and G-52A 0.75 0.29 <0.00001
G-20A and C-44G 0.88 0.17 <0.00001
C-44G and G-52A 0.93 0.13 <0.00001
* p Values derived from chi-square test.Respiratory Research 2006, 7:76 http://respiratory-research.com/content/7/1/76
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ceptibility to infection. Mars and coworkers[16] have
shown that individuals can inherit variable copy numbers
of the DEFA1 and DEFA3 genes, and that the DEFA3 gene
is often absent. Several polymorphisms of beta-defensin-
1 have been reported. [28-31] The frequency of polymor-
phisms in the coding region is low compared with poly-
morphisms in the promoter and untranslated regions. Of
the reported polymorphisms, three polymorphisms in the
5' untranslated region at positions -20, -44, and -52 of the
DEFB1 gene have minor allele frequencies greater than
twenty percent in a white population.[28] The SNP at
position -20 (G-20A) results in the formation of an
nuclear factor-kappaB transcription factor-binding
sequence; however, as DEFB1 is constituatively expressed,
the functional impact is unclear.[30] It has been demon-
strated that DEFB1 function is compromised in cystic
fibrosis.[32] The SNP at position -44 (C-44G) is associ-
ated with Candida carriage in type I diabetics.[33] Varia-
tion in the DEFB1 gene is associated with asthma,[31] a
condition that shares some underlying characteristics with
COPD. The frequency of a SNP in exon 2 (Val38Ile) of the
DEFB1 gene is significantly greater in male Japanese
Table 4: Beta-defensin-1 haplotypes and association with rate of decline in lung function.
Imputed haplotypes (-20/-44/-
52)
Fast decline, n (%) No decline, n (%) p Value*
ACA 24 (4.4) 18 (3.0) 0.26
GCA 181 (32.9) 201 (33.1)
GGA 3 (1.0) 1 (<1.0)
ACG 223 (40.6) 257 (42.3)
GCG 11 (2.0) 11 (1.8)
AGG 6 (1.1) 1 (<1.0)
GGG 102 (18.6) 119 (19.6)
* p Value for global haplotype association calculated with a Wald statistic.
Table 5: Defensin genotypes and infection outcomes.
Polymorphis
m
Genotype Physician 
visits‡§
Part 1 p 
Value*
Part 2 p 
Value†
Days in bed‡ll Part 1 p 
Value*
Part 2 p 
Value†
DEFA1/DEFA3
DEFA1 only 0.22 (0.07) 0.23 0.05 0.38 (0.16) 0.60 0.36
DEFA1/DEFA3 0.28 (0.02) 0.51 (0.06)
DEFB1 G-20A
GG 0.27 (0.04) 0.85 0.88 0.49 (0.10) 0.86 0.98
GA 0.26 (0.03) 0.48 (0.08)
AA 0.30 (0.05) 0.54 (0.11)
DEFB1 C-44G
CC 0.28 (0.03) 0.81 0.42 0.53 (0.07) 0.93 0.14
CG 0.27 (0.04) 0.44 (0.10)
GG 0.18 (0.10) 0.28 (0.24)
DEFB1 G-52A
GG 0.29 (0.04) 0.67 0.62 0.47 (0.08) 0.81 0.29
GA 0.25 (0.03) 0.47 (0.08)
AA 0.30 (0.06) 0.62 (0.14)
Definition of abbreviations: DEFA = alpha-defensin; DEFB = beta-defensin.
*Part 1 of the two-part model involves modeling whether an individual has any physician visits or any days in bed due to lower respiratory infection. 
P values for global haplotype association derived from logistic regression analysis. Decline in lung function status was included as a factor in the 
analysis.
†Part 2 of the two-part model involves modeling the average number of physician visits or days in bed due to lower respiratory infection given that 
it is greater than zero. P values for global haplotype association derived from gamma regression analysis. Decline in lung function status was included 
as a factor in the analysis.
‡Mean (SE).
§Mean number of visits to a physician for lower respiratory infections per year.
llMean number of days kept in bed for lower respiratory infections per year.Respiratory Research 2006, 7:76 http://respiratory-research.com/content/7/1/76
Page 6 of 8
(page number not for citation purposes)
patients with COPD compared with healthy controls.[17]
Our data indicate that this polymorphism is very rare in
whites. More recently, a C-44G polymorphism, but not
the Val38Ile polymorphism, was associated with COPD in
a Chinese population.[18]
Defensins could play a role in the pathogenesis of COPD
and are excellent candidate genes for COPD association
studies due to their expression patterns, location, and
function. First, DEFA1–3 are expressed in neutrophils and
DEFB1 is expressed in airway epithelial cells. Second,
members of the alpha-defensin and beta-defensin fami-
lies are located on chromosome 8p23, a genomic region
linked to the development of airflow obstruction in smok-
ers.[34] Finally, defensins may contribute to the patho-
genesis of COPD by amplifying the cigarette smoke-
induced and the infection-induced inflammatory reac-
tions, which may lead to lung tissue injury.
Table 6: Beta-defensin-1 haplotypes and infection outcomes.
Haplotype Physician 
visits‡§
Part 1 p Value* Part 2 p Value† Days in bed‡ll Part 1 p Value* Part 2 p Value†
ACA 0.26 (0.08) 0.84 0.88 0.60 (0.19) 0.40 0.10
GCA 0.27 (0.03) 0.50 (0.06)
GGA 0.50 (0.27) 2.50 (0.63)
ACG 0.28 (0.02) 0.50 (0.06)
GCG 0.45 (0.11) 1.00 (0.27)
AGG 0.23 (0.20) 0.60 (0.48)
GGG 0.24 (0.04) 0.36 (0.08)
*Part 1 of the two-part model involves modeling whether an individual has any physician visits or any days in bed due to lower respiratory infection. 
P values derived from the Wald statistic based on logistic regression results from Hapassoc. Decline in lung function status was included as a factor 
in the analysis.
†Part 2 of the two-part model involves modeling the average number of physician visits or days in bed due to lower respiratory infection given that 
it is greater than zero. P values derived from the Wald statistic based on gamma regression results from Hapassoc. Decline in lung function status 
was included as a factor in the analysis.
‡Mean (SE).
§Mean number of visits to a physician for lower respiratory infections per year.
llMean number of days kept in bed for lower respiratory infections per year.
Table 7: Frequency of defensin polymorphisms by racial group.
Polymorphism Genotype White (n = 579)† African American (n = 
27)†
p Value*
DEFA1/DEFA3
DEFA1 only 11.1 22.2 0.08
DEFA1/DEFA3 88.9 77.8
DEFB1 G-20A
GG 30.1 44.4 0.21
GA 48.5 44.5
AA 21.4 11.1
DEFB1 C-44G
CC 64.8 100.0 0.0008
CG 30.4 0.0
GG 4.8 0.0
DEFB1 G-52A
GG 40.9 22.2 0.001
GA 44.2 37.1
AA 14.9 40.7
Definition of abbreviations: DEFA = alpha-defensin; DEFB = beta-defensin.
* p Value derived from chi-square test.
†Overall observed SNP frequency (%).Respiratory Research 2006, 7:76 http://respiratory-research.com/content/7/1/76
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We conducted a population-based association study to
determine whether alpha-defensin and beta-defensin pol-
ymorphisms influence smokers' susceptibility to lung
function decline in a large population of white individu-
als. The present genetic association study fulfills the major
criteria for robust association studies[35] and has the fol-
lowing strengths: 1) defensins are excellent COPD candi-
date genes because defensins mediate inflammation and
response to infection in the lung; 2) we included only
white subjects in the association study in order to mini-
mize the potential effects of population stratification; 3)
our study is a large association study involving 579 indi-
viduals; 4) linkage data from a previous study suggests
that 8p23 contains COPD susceptibility genes;[34] and 5)
we have data on the frequency of lower respiratory infec-
tions in the study subjects.
The major concern with unrecognized population stratifi-
cation is that of inflation of the type 1 error rate. However,
there is also a possibility of type 2 error and this may have
influenced the lack of association observed in this study.
The use of unlinked 'genomic control' markers may have
allowed this issue to be examined further. Unfortunately,
genotyping of the requisite number of neutral, genomic
control loci to measure stratification was beyond the
scope of this study.
Analysis of individual polymorphisms and haplotypes
did not suggest any associations between the polymor-
phisms/haplotypes and an increased rate of decline in
lung function in smokers. In addition, the polymor-
phisms were not important predictors of susceptibility to
infection, suggesting that they do not influence DEFA1/
DEFA3-mediated or DEFB1-mediated responses to infec-
tion.
Power analysis indicates that our study was not under-
powered. We estimated that for the DEFA1/DEFA3 copy
number polymorphism, the study design has eighty per-
cent power to detect an association with a relative risk of
1.98. For the DEFB1 -20, -44, and -52 SNPs, the study
design has eighty percent power to detect associations
with relative risks of 1.60, 1.72, and 1.61, respectively.
We found seven DEFB1 haplotypes with estimated fre-
quencies ranging from <1.0% to 42.3% in the subject
group with no decline in lung function. These results are
similar to previously reported data http://innateimmu
nity.net/IIPGA2/index_html. Some of the haplotypes
reported in our study are very rare. In the studies by Dork
et al.[28] and Matsushita et al.[17] where there was a total
of 103 German blood donors and 60 Japanese patients
with COPD, respectively, they may not have had large
enough sample sizes to detect rare haplotypes. In addi-
tion, racial/ethnic differences may account for the differ-
ences observed.
It is known that the frequencies of DEFB1 SNPs differ
between racial/ethnic groups.[30] We determined the
prevalence of the genotypes across white and African
American subjects and found that the DEFB1 G-52A SNP
differed significantly between white and African American
populations. In addition, we did not detect the G allele of
the DEFB1 C-44G SNP in twenty-seven African American
subjects suggesting that this allele is very rare or non-exist-
ent in the African American population. It has been
shown that the C-44G SNP is monomorphic in the Afri-
can American population http://innateimmunity.net/
IIPGA2/index_html.
In interpreting our data, a few limitations should be con-
sidered. To our knowledge, this is the first time the
DEFA1/DEFA3 copy number polymorphism and the
three DEFB1 SNPs have been tested for association with
rate of decline in lung function in any population.
Although we did not find association between the DEFA1/
DEFA3 copy number polymorphism or DEFB1 polymor-
phisms and rate of decline in lung function, these poly-
morphisms may influence other COPD-related
phenotypes. Furthermore, as we have only examined a
few polymorphisms, we have not ruled out the possibility
that other genetic variation in the alpha- and beta-
defensins genes may be associated with the disease. The
genetic basis of COPD may differ between racial/ethnic
groups. We limited the association study to white subjects
and some of the genotype frequencies differ significantly
between white and African American racial groups. There-
fore, it may be of interest to investigate the role of these
polymorphisms in other racial/ethnic populations.
Conclusion
Variation in the DEFB1 gene is associated with COPD in
both Japanese and Chinese populations. Our results indi-
cate that in a white population, the DEFA1/DEFA3 copy
number polymorphism and the three common DEFB1
SNPs at positions -20, -44, and -52 do not influence
smokers' susceptibility to lung function decline or suscep-
tibility to lower respiratory infection.
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